Skip to main content
logo
Daewoong Pharmaceutical Co., Ltd (KRX:069620)
South Korea flag South Korea · Delayed Price · Currency is KRW
128,800
+3,900 (3.12%)
Aug 28, 2026, 3:30 PM KST

Daewoong Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
195,473195,85624,735121,73942,24024,506
Depreciation & Amortization
67,58651,07248,97843,79739,69540,883
Loss (Gain) From Sale of Assets
-52,299-52,328465.97-30,198-246.41,029
Asset Writedown & Restructuring Costs
26,99714,65415,4922,3725,2192,109
Loss (Gain) From Sale of Investments
-17,6584,50624,951-130.674,112-8,308
Loss (Gain) on Equity Investments
23,3116,10723,1531,443374.54-257.52
Stock-Based Compensation
-414.33475.96545.311,6181,8412,005
Provision & Write-off of Bad Debts
4,5543,0572,1925,8352,2502,125
Other Operating Activities
-15,085272.54-6,22610,254-8,8525,813
Change in Accounts Receivable
-35,200-8,563-22,597-478.7-23,193-20,692
Change in Accounts Payable
-11,50723,294-16,67416,59712,408-8,373
Change in Other Net Operating Assets
-23,613-89,199-43,523-36,83842,368-844.34
Operating Cash Flow
162,145149,20551,492136,009118,21539,994
Operating Cash Flow Growth
68.69%189.76%-62.14%15.05%195.58%-60.39%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-266,095-191,534-155,145-109,338-65,227-29,088
Sale of Property, Plant & Equipment
591.49455.143.051,446483.47257.43
Cash Acquisitions
-2,928-2,928--5,807--
Divestitures
---45.59--
Sale (Purchase) of Intangibles
-69,552-49,478-73,858-46,289-46,826-45,633
Investment in Securities
-10,258-3,928-35,557-8,7916,983-13,220
Other Investing Activities
183.93178.53-636.343,12367.5-
Investing Cash Flow
-346,790-247,026-265,451-165,621-106,872-87,683

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-377,97180,000113,74286,15452,352
Long-Term Debt Issued
-310,548325,18765,000149,683108,357
Total Debt Issued
574,764688,519405,187178,742235,837160,709
Short-Term Debt Repaid
--513,468-106,264-87,934-1,212-53,258
Long-Term Debt Repaid
--2,290-92,263-94,201-201,593-91,675
Total Debt Repaid
-392,915-515,758-198,527-182,136-202,805-144,933
Net Debt Issued (Repaid)
181,849172,761206,660-3,39433,03215,776
Issuance of Common Stock
---49,890-40,249
Dividends Paid
-9,047-8,075-7,741-7,278-8,066-6,458
Other Financing Activities
1,623-334.231,702-0-9,450656.41
Financing Cash Flow
174,425164,352200,62139,21815,51750,224

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
5,387-539.934,782-1,052184.471,073
Miscellaneous Cash Flow Adjustments
-0-0-0--
Net Cash Flow
-4,83365,991-8,5568,55527,0443,608

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-103,949-42,329-103,65326,67152,98810,906
Free Cash Flow Growth
----49.67%385.84%-85.36%
Free Cash Flow Margin
-6.36%-2.70%-7.29%1.94%4.14%0.95%
Free Cash Flow Per Share
-9034.39-3678.75-9008.372334.474786.97991.08
Levered Free Cash Flow
-174,757-98,628-174,863-18,388-44,86444,982
Unlevered Free Cash Flow
-165,608-90,831-170,496-9,886-39,61051,387

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
18,41723,61523,08416,60411,4809,839
Cash Income Tax Paid
19,12614,54838,9018,3919,0505,500
Change in Working Capital
-70,320-74,468-82,794-20,72031,583-29,910